The association of a reduced susceptibility to moxifloxacin in causative Clostridium (Clostridioides) difficile strain with the clinical outcome of patients
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F20%3A73605791" target="_blank" >RIV/61989592:15110/20:73605791 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/20:00116176 RIV/00216208:11130/20:10412532 RIV/65269705:_____/20:00072853 RIV/00064211:_____/20:W0000021 and 6 more
Result on the web
<a href="https://aricjournal.biomedcentral.com/articles/10.1186/s13756-020-00765-y#citeas" target="_blank" >https://aricjournal.biomedcentral.com/articles/10.1186/s13756-020-00765-y#citeas</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1186/s13756-020-00765-y" target="_blank" >10.1186/s13756-020-00765-y</a>
Alternative languages
Result language
angličtina
Original language name
The association of a reduced susceptibility to moxifloxacin in causative Clostridium (Clostridioides) difficile strain with the clinical outcome of patients
Original language description
Clostridium difficile, recently reclassified as Clostridioides difficile [1], is a leading pathogen of gastrointestinal infections in hospitalised patients [2]. Between 2005 and 2013, several European multicentre studies aimed at mapping C. difficile epidemiology in Europe and an increase of CDI incidence density was found to be concomitant with changes in prevailing ribotypes; however, the design of the studies varied [3]. To standardize CDI epidemiology data collection, the European centre for disease prevention and control (ECDC) released a surveillance protocol with three options of CDI surveillance intensity (“minimal, light and enhanced”). The “minimal option” collects hospital-level CDI data, the “light version” collects also CDI case-based data, including data on mortality. The “enhanced” option collects hospital data, CDI case based data and microbiological data. Microbiological data includes results on C. difficile isolates ribotyping, the presence of toxins A/B or toxin genes and antimicrobial susceptibility testing to metronidazole, vancomycin and moxifloxacin [3]. While metronidazole and vancomycin are recommended as CDI treatment drugs [4], a reduced susceptibility to moxifloxacin a fluoroquinolone class of drug, is suggested as an epidemiological marker for certain C. difficile ribotypes spread in healthcare settings [5].
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
10606 - Microbiology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Antimicrobial Resistance and Infection Control
ISSN
2047-2994
e-ISSN
—
Volume of the periodical
9
Issue of the periodical within the volume
98
Country of publishing house
GB - UNITED KINGDOM
Number of pages
7
Pages from-to
"'98(1)'"-"'98(7)'"
UT code for WoS article
000552013900002
EID of the result in the Scopus database
2-s2.0-85087419563